Nautilus Biotechnology, INC. (NAUT) — SEC Filings

Overview

Nautilus Biotechnology, INC. (NAUT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 4, 2025: Nautilus Biotechnology, Inc. filed an 8-K on November 4, 2025, reporting an event that occurred on November 3, 2025. The filing is categorized under 'Other Events' and does not specify any material agreements, asset acquisitions, or executive changes. The company, formerly known as ARYA Sciences Acq

Sentiment Summary

Across 16 filings, the sentiment breakdown is: 2 bearish, 13 neutral, 1 mixed. The dominant filing sentiment for Nautilus Biotechnology, INC. is neutral.

Filing Type Overview

Nautilus Biotechnology, INC. (NAUT) has filed 6 8-K, 6 10-Q, 2 10-K, 1 SC 13D/A, 1 DEF 14A with the SEC between Feb 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (16)

• Nautilus Biotechnology Files 8-K Under 'Other Events' — 8-K · Nov 4, 2025 Risk: low
  Nautilus Biotechnology, Inc. filed an 8-K on November 4, 2025, reporting an event that occurred on November 3, 2025. The filing is categorized under 'Other Even
• Nautilus Biotech Narrows Q3 Loss Amidst Reduced R&D Spend — 10-Q · Oct 28, 2025 Risk: high
  Nautilus Biotechnology, Inc. (NAUT) reported a net loss of $13.574 million for the three months ended September 30, 2025, an improvement from a net loss of $16.
• Nautilus Biotech Posts Zero Revenue, Widens Q2 Loss to $28.5M — 10-Q · Jul 31, 2025 Risk: high
  Nautilus Biotechnology, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, as the company remain
• Nautilus Biotechnology Files 8-K on Shareholder Vote — 8-K · Jun 23, 2025 Risk: low
  Nautilus Biotechnology, Inc. filed an 8-K on June 23, 2025, reporting on matters submitted to a vote of security holders on June 20, 2025. The company, formerly
• Nautilus Biotechnology Faces Delisting Concerns — 8-K · May 2, 2025 Risk: high
  Nautilus Biotechnology, Inc. filed an 8-K on May 1, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company was former
• Nautilus Biotechnology Files Q1 2025 10-Q — 10-Q · Apr 29, 2025 Risk: medium
  Nautilus Biotechnology, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as ARYA Sciences Acquisition Corp III,
• 10-K Filing — 10-K · Feb 27, 2025
• Nautilus Biotechnology Announces Board and Executive Changes — 8-K · Jan 31, 2025 Risk: medium
  Nautilus Biotechnology, Inc. announced on January 27, 2025, changes in its board of directors and executive compensation. Specifically, the company reported the
• Perceptive Advisors Updates Nautilus Biotech Stake — SC 13D/A · Nov 14, 2024 Risk: medium
  Perceptive Advisors LLC, through its affiliated entities Perceptive Life Sciences Master Fund, Ltd. and Joseph Edelman, has amended its Schedule 13D filing for
• Nautilus Biotechnology Files Q3 2024 10-Q — 10-Q · Oct 29, 2024 Risk: medium
  Nautilus Biotechnology, Inc. filed its quarterly report for the period ending September 30, 2024. The company, formerly known as ARYA Sciences Acquisition Corp
• Nautilus Biotechnology Files Q2 2024 10-Q — 10-Q · Jul 30, 2024 Risk: medium
  Nautilus Biotechnology, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business
• Nautilus Biotechnology Files 8-K on Shareholder Vote Matters — 8-K · Jun 13, 2024 Risk: medium
  Nautilus Biotechnology, Inc. filed an 8-K on June 13, 2024, to report on matters submitted to a vote of its security holders. The filing indicates a change in t
• Nautilus Biotechnology, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · Apr 30, 2024 Risk: low
  Nautilus Biotechnology, Inc. (NAUT) filed a Quarterly Report (10-Q) with the SEC on April 30, 2024. Nautilus Biotechnology, Inc. filed a 10-Q report for the per
• Nautilus Biotechnology, Inc. Announces Annual Meeting of Stockholders — DEF 14A · Apr 26, 2024 Risk: low
  Nautilus Biotechnology, Inc. (NAUT) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. The annual meeting of Nautilus Biotechnology, Inc. stockho
• Nautilus Biotechnology, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 28, 2024 Risk: low
  Nautilus Biotechnology, Inc. (NAUT) filed a Annual Report (10-K) with the SEC on February 28, 2024. Nautilus Biotechnology, Inc. filed its annual report on Form
• Nautilus Biotechnology Enters Material Definitive Agreement — 8-K · Feb 28, 2024 Risk: medium
  Nautilus Biotechnology, Inc. filed an 8-K on February 28, 2024, to report an entry into a material definitive agreement. The filing indicates that the company,

Risk Profile

Risk Assessment: Of NAUT's 15 recent filings, 3 were flagged as high-risk, 7 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Nautilus Biotechnology, INC.'s most recent 10-Q filing (Oct 28, 2025):

• Net Income: -$13.574M
• EPS: -$0.11
• Cash Position: $131.4M
• Total Assets: $200.915M

Key Executives

• Joseph Edelman
• Alexander Rakitin
• Sujal Patel

Industry Context

Nautilus Biotechnology operates in the highly competitive and rapidly evolving biotechnology sector. The industry is characterized by significant investment in research and development, long product development cycles, and stringent regulatory hurdles. Companies like Nautilus focus on developing novel technologies for biological analysis, aiming to disrupt traditional methods and accelerate scientific discovery.

Top Tags

Biotechnology (4) · 10-Q (4) · financials (3) · biotechnology (3) · Nautilus Biotechnology (3) · corporate-event (2) · Proteomics (2) · Net Loss (2) · corporate-governance (2) · shareholder-vote (2)

Key Numbers

• SEC File Number: 001-39434 — Identifies the company's filing history with the SEC.
• IRS Employer Identification No.: 98-1541723 — Company's tax identification number.
• Net Loss (Q3 2025): $13.574M — Improved from $16.446M in Q3 2024
• Net Loss (YTD Sept 2025): $45.220M — Improved from $53.186M in YTD Sept 2024
• Total Operating Expenses (Q3 2025): $15.472M — Decreased from $19.100M in Q3 2024
• Research & Development Expenses (Q3 2025): $9.605M — Decreased from $12.288M in Q3 2024
• Cash & Short-term Investments (Sept 30, 2025): $131.4M — Sufficient for at least next 12 months of operations
• Accumulated Deficit (Sept 30, 2025): $318.2M — Indicates significant historical losses
• Net Cash Used in Operating Activities (YTD Sept 2025): $38.321M — Reduced from $44.836M in YTD Sept 2024
• Shares Outstanding (Oct 23, 2025): 126,305,122 — Reflects slight increase from 126,106,176 at Dec 31, 2024
• Revenue: $0 — No revenue reported for Q2 2025 or H1 2025, consistent with prior periods.
• Net Loss (Q2 2025): -$28.5M — Increased from -$27.9M in Q2 2024, indicating widening losses.
• Net Loss (H1 2025): -$57.2M — Increased from -$55.1M in H1 2024, reflecting continued operational expenses.
• R&D Expenses (Q2 2025): $20.1M — Up from $19.5M in Q2 2024, showing ongoing investment in product development.
• G&A Expenses (Q2 2025): $8.4M — Increased from $8.0M in Q2 2024, indicating higher administrative costs.

Related Companies

ARIA · ARYA

Frequently Asked Questions